Tsimihodimos Vasilis, Karabina Sonia-Athena P, Tambaki Afroditi P, Bairaktari Eleni, Goudevenos John A, Chapman M John, Elisaf Moses, Tselepis Alexandros D
Department of Internal Medicine, University of Ioannina, Ioannina, Greece.
Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):306-11. doi: 10.1161/hq0202.102918.
Human plasma platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A(2) that is primarily associated with low density lipoprotein (LDL). PAF-AH activity has also been found in high density lipoprotein (HDL), although it has recently been indicated that there is no PAF-AH protein in HDL. Plasma paraoxonase 1 (PON1) is an HDL-associated esterase, which also exhibits PAF-AH-like activity. The effect of atorvastatin (20 mg per day for 4 months) on PAF-AH and PON1 activities in patients with dyslipidemia of type IIA (n=55) or type IIB (n=21) was studied. In both patient groups, atorvastatin significantly reduced plasma PAF-AH activity because of the decrease in LDL plasma levels and the preferential decrease in PAF-AH activity on dense LDL subfractions (LDL-4 and LDL-5). Drug therapy did not affect HDL-associated PAF-AH activity or serum PON1 activities toward paraoxon and phenylacetate in either patient group. However, because of the reduction in LDL cholesterol levels, the ratios of HDL-associated PAF-AH and serum PON1 activities to LDL cholesterol levels were significantly increased after drug administration. The reduction of the LDL-associated PAF-AH activity and the elevation in the ratios of HDL-associated PAF-AH and PON1 activities to LDL plasma levels may represent a new dimension in the antiatherogenic effect of atorvastatin.
人血浆血小板活化因子乙酰水解酶（PAF-AH）是一种磷脂酶A(2)，主要与低密度脂蛋白（LDL）相关。PAF-AH活性也在高密度脂蛋白（HDL）中被发现，尽管最近有研究表明HDL中不存在PAF-AH蛋白。血浆对氧磷酶1（PON1）是一种与HDL相关的酯酶，也表现出类似PAF-AH的活性。本研究探讨了阿托伐他汀（每天20 mg，持续4个月）对IIA型（n = 55）或IIB型（n = 21）血脂异常患者PAF-AH和PON1活性的影响。在两组患者中，阿托伐他汀均显著降低了血浆PAF-AH活性，这是由于LDL血浆水平降低以及致密LDL亚组分（LDL-4和LDL-5）上PAF-AH活性优先降低所致。药物治疗对两组患者中与HDL相关PAF-AH活性或血清PON1对对氧磷和苯乙酸的活性均无影响。然而，由于LDL胆固醇水平降低，给药后与HDL相关PAF-AH和血清PON1活性与LDL胆固醇水平的比值显著增加。LDL相关PAF-AH活性的降低以及与HDL相关PAF-AH和PON1活性与LDL血浆水平比值的升高可能代表了阿托伐他汀抗动脉粥样硬化作用的一个新方面。
